

Note

Synthesis of newer selenadiazoles and thiadiazoles from their chroman-4-one precursors

M S Gaikwad, A S Mane, R V Hangarge,
V P Chavan & M S Shingare*

Department of Chemistry, Dr. Babasaheb Ambedkar Marathwada
University, Aurangabad 431 004, India.

Received 16 May 2000; accepted (revised) 24 May 2002


A newer series of 13 compounds viz. 2-aryl-3,4-dihydrobenzopyrano [3, 4-*d*]-1, 2, 3-selenadiazoles **3** and 2-aryl-3,4-dihydrobenzopyrano [3,4-*d*]-1, 2, 3-thiadiazoles **4** have been synthesized from their chroman-4-one precursors.

Substituted chroman-4-ones, a class of oxygen heterocycles are common among the natural products and are extensively used as synthetic intermediates¹. They have been used to prepare various fused heterocyclic ring systems and have been used for a wide range of pharmacological activity². Some chroman-4-ones with medical use are khellin, a coronary vasodilator^{3,4}, chroman-4-one-2-carboxylic acids, a spasmolytic agent and disodium chromoglycate, and an anti-allergenic drug⁵.

On the other hand, it is well known that a number of heterocyclic compounds containing nitrogen and sulfur exhibit a wide variety of biological activities. However, reports about selenium containing heterocycles are relatively less⁶⁻⁸, although some of them are used as chemotherapeutic agents⁹; also some 1, 3, 4- and 1, 2, 3- seleno/thiadiazoles were found to possess significant antibacterial and antiviral activities^{7,10}.

The fused ring systems of chroman-4-ones are found to possess enhanced biological activities and the synthesis of the title heterocycles (selenadiazoles and thiadiazoles) is of growing interest, say, 1,2,3-seleno/thiadiazole rings, worked out by Bhaskar Reddy *et al.*¹¹⁻¹⁹ fused to carbocyclic/heterocyclic rings. Therefore, as a part of continuation of our work²⁰ on chromone nucleus, it was thought to synthesize 1,2,3-seleno/thiadiazoles fused to chroman-4-ones.

A series of such compounds as 2-aryl-3,4-dihydrobenzopyrano [3, 4-*d*]-1,2,3-selenadiazoles **3** and 2-aryl-3,4-dihydrobenzopyrano [3, 4-*d*]-1, 2, 3-thiadiazoles **4** have been synthesized (**Scheme I**). The carbonyl function in **1** (chroman-4-ones) has been exploited for the synthesis of selenadiazoles **3** and



Scheme I

thiadiazoles **4**. Chroman-4-ones **1** on condensation with semicarbazide hydrochloride gave its semicarbazones **2** which on SeO₂ oxidation afforded **3**.

On the other hand, **2** on treatment with thionyl chloride at -10 to 0°C yielded **4**. The formation of the compounds **3** and **4** was confirmed as there were no characteristic absorptions at 3400 cm⁻¹ (NH) and 3200cm⁻¹ (NH₂) and on the other hand the characteristic absorption bands for compounds **3** and **4** were observed at 1475 and 1487 (N=N), 700 (N-S-C), 685 (C-Se-N), 700 cm⁻¹(C-S-N), respectively. Also ¹H NMR spectra for compounds **3** and **4** gave added confirmation for their formation as the spectra displayed peaks at δ 7.0-8.2 (8H, Ar-H) and at 6.6(s, O-C-H).

Experimental Section

Melting points were taken in open capillaries in paraffin oil-bath and are uncorrected. The purity of the compounds was checked on TLC. IR spectra were recorded in nujol on a Perkin- Elmer 337 spectrophotometer (λ max in cm⁻¹); and ¹H NMR spectra on a Varian Gemini 200 MHz spectrometer using TMS as internal standard (chemical shifts in δ, ppm).

2-(4-Chlorophenyl)-3,4-dihydrobenzopyrano [3, 4-*d*]-1, 2, 3-selenadiazoles 3b. Compound **2** (R= *p*-Cl,

1.5 g, 0.005mole) was dissolved in 15-20 mL of acetic acid, warmed the solution in oil-bath to 60°C. To this was added SeO₂ (0.55g, 0.005 mole) portionwise with constant stirring maintaining the temperature at 60°C. After the complete transfer of SeO₂ the reaction mixture was stirred for 3 hr maintaining the same temperature. The mixture was then cooled to room temperature, and poured on crushed ice, and digested for 30 min. The precipitate thus obtained was filtered, dried and purified by column chromatography to give the product **3b**; yield 84%, m.p. 128°C; (**Table I**) IR (Nujol): 1475(N=N), 1220(C-O-C), 680(C-Se-N) cm⁻¹; ¹H NMR (200MHz, CDCl₃): δ 7.2-8.2(m, 8H, Ar-H), 6.6(s, 1H, O-C-H); Mass: (M⁺- 348), (M⁺²-350), m/z 319 (98% aban.), 285(100% base peak), 205(45%),

176(75%); ¹³C NMR: δ 78.41(C-2), 116.78 (C-9), 117.85(C-8), 122.81(C-6), 124.94(C-7), 127.96(C-5), 129.06(C-1'), 130.35(C-2', C-6'), 135.20(C-3', C-5'), 138.40(C-4'), 151.89(C-3), 153.50(C-4), 159.46(C-10). **3d**: ¹H NMR: δ 6.8-7.5(m, Ar-H, 8H), 6.5(s, O-C-H, 1H), 2.5(s, 3H, CH₃). **3e**: ¹H NMR: δ 7.5-8.2(m, 8H, Ar-H), 6.8(s, 1H, O-C-H).

2-(4-Chlorophenyl)-3,4-dihydrobenzopyrano [3,4-d]-1,2,3-thiadiazoles 4b. Redistilled thionyl chloride (5 mL) was taken in clean, dry 50 mL round bottom flask kept in a salt ice-bath and the temperature allowed to fall down up to -10°C. To it was added with constant magnetic stirring 1.578 g of compound **2b** (R=*p*-Cl, 0.005 mole) in portions maintaining the temperature below 0°C. After the complete addition,

Table I—Characterization data of compounds **3a-m** and **4a-m**

Compd	R	m.p. (°C)	Yield (%)	Found (%) (Calcd)			Compd	R	m.p. (°C)	Yield (%)	Found (%) (Calcd)		
				C	H	N					C	H	N
3a	C ₆ H ₅	148	68	57.48 (57.51)	3.17 3.19	8.93 8.94	4a	C ₆ H ₅	182	78	67.64 (67.66)	3.72 3.75	10.49 10.52
3b	<i>p</i> -Cl-C ₆ H ₄	128	84	51.78 (51.80)	2.56 2.59	8.02 8.05	4b	<i>p</i> -Cl-C ₆ H ₄	115	85	59.87 (59.90)	2.96 2.99	9.30 9.31
3c	<i>p</i> -MeO-C ₆ H ₄	173	69	55.96 (55.98)	3.45 3.49	8.15 8.16	4c	<i>p</i> -MeO-C ₆ H ₄	108	64	64.83 (64.86)	4.03 4.05	9.51 9.54
3d	<i>p</i> -Me-C ₆ H ₄	205	78	58.69 (58.72)	3.65 3.67	8.53 8.56	4d	<i>p</i> -Me-C ₆ H ₄	162	72	68.56 (68.57)	4.25 4.28	9.98 10.00
3e	<i>p</i> -NO ₂ -C ₆ H ₄	98	66	58.26 (58.28)	2.48 2.51	11.70 11.73	4e	<i>p</i> -NO ₂ -C ₆ H ₄	178	80	57.85 (57.87)	2.88 2.89	13.47 13.50
3f	<i>o</i> -OH-C ₆ H ₄	131	63	54.69 (54.71)	3.00 3.03	8.49 8.51	4f	<i>o</i> -OH-C ₆ H ₄	118	60	63.79 (63.82)	3.51 3.54	9.90 9.92
3g	<i>o</i> -Cl-C ₆ H ₄	78	71	51.77 (51.80)	2.57 2.59	8.04 8.05	4g	<i>o</i> -Cl-C ₆ H ₄	171	80	59.87 (59.90)	2.97 2.99	9.28 9.31
3h	<i>m</i> -Cl-C ₆ H ₄	100	60	51.79 (51.80)	2.56 2.59	8.02 8.05	4h	<i>m</i> -Cl-C ₆ H ₄	148	69	59.88 (59.90)	2.96 2.99	9.29 9.31
3i	(MeO) ₃ C ₆ H ₂	184	81	53.57 (53.60)	3.95 3.97	6.7 6.9	4i	(MeO) ₃ C ₆ H ₂	98	82	60.64 (60.67)	4.46 4.49	7.84 7.86
3j	Cinnamyl	112	77	57.48 (57.51)	3.18 3.19	8.92 8.94	4j	Cinnamyl	130	73	67.63 (67.66)	3.72 3.75	10.49 10.52
3k	Furyl	139	65	51.46 (51.49)	2.61 2.64	8.21 8.24	4k	Furyl		81	60.92 (60.93)	3.09 3.12	10.90 10.93
3l	<i>o</i> -Me C ₆ H ₄	104	70	58.70 (58.72)	3.64 3.67	8.55 8.56	4l	<i>o</i> -Me-C ₆ H ₄	120	76	68.54 (68.57)	4.25 4.28	9.98 10.00
3m	<i>m</i> -Me-C ₆ H ₄	176	58	58.69	3.65	8.52	4m	<i>m</i> -Me-C ₆ H ₄	138	70	68.56 (68.57)	4.26 4.28	9.97 10.00

Solvent for crystallization: Ethanol

temperature was allowed to rise to room temperature and 30 mL of dichloromethane was added. The mixture was stirred for further 1 hr. Excess thionyl chloride was decomposed using saturated NaHCO₃ solution and the product **4b** isolated using extractive isolation technique. Further purification was achieved by column chromatography, yield 86 %, mp 115°C (**Table I**); IR (Nujol): 1487(N=N), 1230(C-O-C), 700 (C-S-N) cm⁻¹; ¹H NMR (200MHz, CDCl₃): δ 7.0-8.2 (m, 8H, ArH), 6.7(s, 1H, O-C-H); Mass: (M⁺-300), M⁺-302, m/z 271(100% base peak), 237(95%), 228(10%), 208(20%), 165(15%) etc.

4d: ¹H NMR: δ 7.0-7.5(m, Ar-H, 8H), 6.2(s, O-C-H, 1H), 2.6(s, CH₃ group, 3H). **4e**: ¹H NMR: δ 7.5-8.4(m, Ar-H, 8H), 6.7(s, O-C-H, 1H).

Acknowledgement

The authors are thankful to the Head, Department of Chemistry, Dr B A Marathwada University for providing necessary facilities. We are thankful to Drs P P Wadgaonkar and B M Bhawal, NCL, Pune for providing spectral and elemental analysis. One of the authors (MSG) is thankful to the Principal, P L Deshmukh, Yogeshwari Mahavidyalaya Ambejogi for his kind help and also thankful to UGC, New Delhi for awarding Teacher Research Fellowship under faculty improvement programme.

References

- 1 Ellis G P, *Chromenes, Chromanones and Chromones*, (John Wiley, New York), **1977**.
- 2 Cox J S G, Beach J E, Blair A M J N, Clarke A J, Kind J, Lee T B, Laueday D E E, Moss G F, Org T S C, Ritchie J T & Sheard R, *Adv Drug Res*, **1970**, 5115.
- 3 Geissmann T A & Halsall T G, *J Am Chem Soc*, **73**, **1951** 1280.
- 4 Clarrge J R & Robertson A, *J Chem Soc*, **1949**, 302.
- 5 Fitzmaerice C & Wragg A H, *Brit Patent*, **1965**,1,632,362; *Chem Abstr*, **65**,**1966**, 34441.
- 6 Sharma K S & Singh S P, *Indian J Chem*, **31B**, **1992**, 396.
- 7 Lalezari I, Shafiee A & Yazdani S, *J Pharm Sci*, **63**, **1974**, 628 and references cited therein.
- 8 Sharma K S, Sarita & Shardakumari, *Indian J Heterocycl Chem*, **4**, **1994**, 137.
- 9 Klayman D L & Gunther W H H, *Organic selenium compounds. their chemistry and biology* (Washington, New York), **1972**.
- 10 Shafiee A, Lalezari I, Yazdani S & pournorouz A, *J Pharm Sci*, **62**,**1973**, 839.
- 11 Bhaskar Reddy D, Somasekhar Reddy A & Padmavathi V, *J Chem Res*, (6), **1998**,785.
- 12 Bhaskar Reddy D, Ramana Reddy M V & Padmavathi V, *Indian J Chem*, **36B**, **1997**, 923 and references cited therein.
- 13 Bhaskar Reddy D, Somasekhar Reddy A & Padmavathi V, *Phosphorus, Sulfur and Silicon related elements*, **122**,**1997**,143.
- 14 Bhaskar Reddy D, *Indian J Chem*, **38B**, **1990**, 1342.
- 15 Bhaskar Reddy D, Ramana Reddy M V & Padmavathi V, *Synth Commun*, **29**(4), **1999**, 667.
- 16 Bhaskar Reddy D, Ramana Reddy M V, Padmaja A & Padmavathi V, *Phosphorus, Sulfur and Silicon related elements*, **141**,**1998**,191.
- 17 Bhaskar Reddy D, Balaiah, Padmavathi V & Padmaja A, *Heterocycl Comm*, **5**(3), **1999**, 285.
- 18 Padmavathi V, Padmaja A & Bhaskar Reddy D, *Indian J Chem*, **38B**, **1999**, 308.
- 19 Bhaskar Reddy D, Somasekhar Reddy A & Padmavathi V, *Indian J Chem*, **37B**, **1998**, 1194.
- 20 Karale B K, Gill C H, Ganage K N, Bachute M T & Shingare M S, *Indian J Heterocycl Chem*, **9**,**1999**,153.